Corvus Pharmaceuticals Inc
CRVS
Company Profile
Business description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Contact
863 Mitten Road
Suite 102
BurlingameCA94010
USAT: +1 650 900-4520
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,629.10 | 51.40 | -0.59% |
| CAC 40 | 7,892.61 | 55.21 | 0.70% |
| DAX 40 | 21,411.53 | 157.26 | 0.74% |
| Dow JONES (US) | 44,492.36 | 335.63 | 0.76% |
| FTSE 100 | 8,565.20 | 20.07 | 0.23% |
| HKSE | 19,700.56 | 78.21 | -0.40% |
| NASDAQ | 19,961.03 | 48.31 | -0.24% |
| Nikkei 225 | 39,958.87 | 312.62 | 0.79% |
| NZX 50 Index | 13,060.08 | 22.94 | 0.18% |
| S&P 500 | 6,099.01 | 12.64 | 0.21% |
| S&P/ASX 200 | 8,378.70 | 51.10 | -0.61% |
| SSE Composite Index | 3,230.16 | 16.54 | 0.51% |